Topical sirolimus therapy for epidermal nevus with features of acanthosis nigricans

Pediatr Dermatol. 2019 Jul;36(4):554-555. doi: 10.1111/pde.13833. Epub 2019 Apr 15.

Abstract

We present a 4-year-old developmentally appropriate boy with short stature and widespread expanding epidermal nevus with features of acanthosis nigricans. He was found to have a mosaic mutation in FGFR3, the R248C variant. Despite several therapies, he continued to have growth, fissuring, and bleeding of the affected skin. Ultimately, topical sirolimus was attempted and found to improve thickness and overall symptoms.

Keywords: FGFR3; acanthosis nigricans; epidermal nevus; topical sirolimus.

Publication types

  • Case Reports

MeSH terms

  • Acanthosis Nigricans / genetics
  • Acanthosis Nigricans / pathology*
  • Administration, Topical
  • Child, Preschool
  • Diagnosis, Differential
  • Gene Expression Regulation
  • Humans
  • Male
  • Mutation
  • Nevus / drug therapy*
  • Nevus / genetics*
  • Nevus / pathology
  • Receptor, Fibroblast Growth Factor, Type 3 / genetics*
  • Risk Assessment
  • Sirolimus / therapeutic use*
  • Treatment Outcome

Substances

  • FGFR3 protein, human
  • Receptor, Fibroblast Growth Factor, Type 3
  • Sirolimus

Supplementary concepts

  • Epidermal Nevus